8-K: 4D Molecular Therapeutics Reports Positive Full Year 2024 Results, Advances Pipeline

4D Molecular Therapeutics announces full year 2024 financial results, operational highlights, and upcoming milestones, highlighting progress in wet AMD, DME, and cystic fibrosis programs.

Summary

• 4D Molecular Therapeutics (4DMT) reported its full year 2024 financial results and provided operational highlights.
• The company has strategically focused its pipeline on 4D-150 for wet AMD and DME, and 4D-710 for cystic fibrosis.
• 4DMT paused investment in other programs to extend its cash runway.
• Positive interim data was presented for 4D-150 in wet AMD and DME clinical trials.
• The FDA has aligned with 4DMT on a single Phase 3 trial being acceptable for BLA submission for 4D-150 in DME.
• 4FRONT Phase 3 program in wet AMD is on track, with initiation of 4FRONT-1 expected in March 2025 and 4FRONT-2 in Q3 2025.
• Topline data from both 4FRONT studies are expected in the second half of 2027.
• Cash, cash equivalents, and marketable securities totaled $505 million as of December 31, 2024, expected to fund planned operations into 2028.
• Research and development expenses were $141.3 million for 2024, compared to $97.1 million for 2023.
• General and administrative expenses were $46.6 million for 2024, compared to $36.5 million for 2023.
• Net loss was $160.9 million for 2024, compared to a net loss of $100.8 million for 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data, FDA alignment, and a healthy cash position. The strategic pipeline focus and extended cash runway contribute to a favorable sentiment.

Positives

• Positive interim data from PRISM and SPECTRA clinical trials for 4D-150 in wet AMD and DME.
• FDA alignment on a single Phase 3 trial for BLA submission for 4D-150 in DME.
• 4FRONT Phase 3 program in wet AMD is on track.
• Extended cash runway into 2028 due to strategic pipeline focus.
• Strong cash position of $505 million as of December 31, 2024.

Negatives

• Increased net loss of $160.9 million for 2024 compared to $100.8 million for 2023.
• Increased research and development expenses to $141.3 million in 2024.
• Increased general and administrative expenses to $46.6 million in 2024.
• Paused investment in some therapeutic programs pending additional financing or partnerships.

Risks

• Clinical trial outcomes may not be as positive as interim data suggests.
• Regulatory approval may not be granted for 4D-150 or other product candidates.
• Competition in the retinal vascular disease and cystic fibrosis treatment spaces.
• The company may need to raise additional capital in the future.
• Uncertainties related to enrollment rates in Phase 3 studies.

Future Outlook

4DMT expects its cash, cash equivalents, and marketable securities to be sufficient to fund planned operations into 2028, including full execution and topline data from 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials in wet AMD, and ongoing Phase 1 & 2 clinical development of 4D-150 in DME and 4D-710 in CF.

Management Comments

• 2024 was a landmark year for 4DMT, driven by groundbreaking clinical advancements toward Phase 3 trials that position us for even greater success in 2025 and beyond, said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
• The data from the PRISM and SPECTRA clinical trials have highlighted 4D-150's potential to become the first backbone therapy for retinal vascular diseases by providing patients and physicians with long-lasting and continuous disease control, plus freedom from frequent bolus injections.
• 4D-150s target product profile is designed to allow for seamless adoption into retina clinic practices and for pricing flexibility augmented by our low cost of goods.
• We believe rapid enrollment in 4D-150 Phase 3 studies that mirror enrollment rates seen in our Phase 1/2 studies would validate the potential for future widespread adoption of 4D-150 in retina clinics, strengthening our path toward transforming the retinal vascular disease treatment paradigm.

Industry Context

4DMT is positioning itself as a leader in gene therapy for retinal and pulmonary diseases. The focus on durable, single-injection treatments addresses a significant unmet need in these markets, potentially disrupting existing treatment paradigms that rely on frequent injections or chronic medication.

Comparison to Industry Standards

• The reported 83% reduction in injection burden for wet AMD with 4D-150 compares favorably to current standard of care treatments like aflibercept (Eylea) and ranibizumab (Lucentis), which require frequent injections.
• The +8.4 letter gain in BCVA and -194 μm reduction in CST for DME patients treated with 4D-150 are competitive with other DME therapies.
• The company's cash runway into 2028 provides a significant advantage compared to smaller biotech companies that often face near-term funding challenges.
• Companies like Adverum Biotechnologies and REGENXBIO are also developing gene therapies for wet AMD, but 4DMT appears to be further along in clinical development with its 4FRONT Phase 3 program.

Stakeholder Impact

• Shareholders: Positive clinical data and extended cash runway are likely to be viewed favorably.
• Patients: Potential for new, more effective treatments for wet AMD, DME, and cystic fibrosis.
• Employees: Job security and potential for career advancement due to company's progress.
• Suppliers: Continued business opportunities as clinical trials progress.

Next Steps

• Initiate 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials for wet AMD in March and Q3 2025, respectively.
• Present 2-year data from Phase 1/2a and 18-month data from Phase 2b cohorts of PRISM clinical trial in Q4 2025.
• Provide 52-week interim data update from Part 1 of SPECTRA at a scientific conference in Q3 2025.
• Present interim data and program update from AEROW clinical trial at a scientific conference in H2 2025.
• Deliver primary endpoint 52-week topline data from both 4FRONT-1 and 4FRONT-2 in H2 2027.

Key Dates